login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Biotech Firm Unveils Fast-Acting Impotency Drug
"The magnitude of success in the first 15 minutes was surprising," Leland Wilson, the company's CEO, said in a statement.
Wilson put the spotlight on upbeat results for the class three investigational drug to treat male impotency, now in its last step before it can get a green light from the Food and Drug Administration (FDA).
"This new data further strengthens the profile and differentiation of avanafil from other currently available oral ED therapies," Wilson said, referring to erectile dysfunction.
While "we knew from the pharmacokinetic profile that avanafil works very quickly, this data is exciting evidence of how fast avanafil really works," he stressed.
"From our discussions with patients and physicians, we knew that rapid onset was an important attribute in the selection of an ED therapy," he added.
Knowing avanafil acts in 15 minutes and lasts the length of a sexual encounter should be huge pluses for the drug in this highly lucrative market, said Dr Charles Bowden with Vivus.
The company is eyeing a market launch in early 2012.
Pfizer, which makes Viagra, says its drug acts within 30 minutes to an hour after it is taken. Cialis, made by Eli Lilly, starts working from 30 minutes to six hours after ingestion.
A third competitor, Levitra, acts starting between 25 and 60 minutes after it is taken.
A recent report by the American College of Physicians published in October found that some 322 million men worldwide will have erectile dysfunction by 2020.
Source-AFP
SRM
|
|
More News on: Drug Toxicity, Signature Drug Toxicity, Andropause / Male Menopause, Premature Ejaculation
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
- News Quick Links
 | News Central | | Health Watch | |
| Latest Health News | | Health In Focus | |
| News Category (500+) | | Breaking Health News | |
| Popular News | | Celebrating Life | |
| Health News and Press Release | | Medindia - Exclusive | |
| News Photo Gallery | | India Special | |
| News Video Gallery | | Lifestyle and Wellness | |
| News From Other Resources | |||
| News Categories: |
| » | Revision in Quality Standards for Heparin |
| » | Acne Drug Users At High Risk of Developing Eye Infections |
| » | Patients Who Take Antidepressants When in ICU More Likely to Die |
| » | New Tablet Coating Product by Ideal Cures, In Geneva |
| » | Prednisolone Benefits Patients With Bell's Palsy |
| More Drug News | |
|
Drug Related News |
||||||||
| » | Revision in Quality Standards for Heparin | » | Acne Drug Users At High Risk of Developing Eye Infections | |||||
| » | Patients Who Take Antidepressants When in ICU More Likely to Die | » | New Tablet Coating Product by Ideal Cures, In Geneva | |||||
| » | Prednisolone Benefits Patients With Bell's Palsy | » | 'Orphan' Sleep Drug may Fight Cancer | |||||
| » | New Drugs for Fox Tapeworm Infection | » | Poor Quality Antimalarial Drugs Pose Threat | |||||
| Read More >> | ||||||||
